NL-OMON45872已完成不适用
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients - 20140207
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* 18 to * 45 years of age at time of screening.
- •Migraine headaches without aura * 6 months prior to screening.
- •* 1 and * 5 migraine days per month in each of the 3 months prior to screening.
排除标准
- •History of migraine with aura, cluster headachte or hemiplegic migraine headache.
- •Other headache disorders (except for episodic tension-type headache <5days/month.
- •Recent nicotine or tobacco users (should have stopped approximately 6 months prior to screening).
- •Pregnant or breastfeeding women.
- •More exclusion criteria can be found on page 33 to 36 of the protocol amendment 4 dd 21Oct16
研究者
相似试验
已完成
不适用
Double Blind, Randomized, Parallel-group, Single-dose, Comparative Pharmacokinetic, Safety, Tolerability Study of Exemptia injection, solution for subcutaneous use with Humira® (Adalimumab) injection.CTRI/2016/05/006948RusBiopharm LLC Russia100
进行中（未招募）
1 期
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisActive Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2021-005947-58-CZMoonLake Immunotherapeutics AG200
进行中（未招募）
1 期
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisActive Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2021-005947-58-HUMoonLake Immunotherapeutics AG200
进行中（未招募）
1 期
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisEUCTR2021-005947-58-ESMoonLake Immunotherapeutics AG200
进行中（未招募）
1 期
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisEUCTR2021-005947-58-BGMoonLake Immunotherapeutics AG200